Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0321 has been discontinued.
View all Non-selective Ionotropic Glutamate products.Broad spectrum EAA ligand.
S-enantiomer and R-enantiomer also available.
分子量 | 195.17 |
公式 | C9H9NO4 |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 7292-81-1 |
PubChem ID | 5115 |
InChI Key | VTMJKPGFERYGJF-UHFFFAOYSA-N |
Smiles | NC(C(O)=O)C1=CC=C(C(O)=O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
关键词: (RS)-4-Carboxyphenylglycine, (RS)-4-Carboxyphenylglycine supplier, Broad, spectrum, EAA, ligand, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, (RS)-4CPG, Non-selective, mGlu, 0321, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 (RS)-4-Carboxyphenylglycine 的部分引用包括:
Singh et al (2006) Altered balance of glutamatergic/GABAergic synaptic input and associated changes in dendrite morphology after BDNF expression in BDNF-deficient hippocampal neurons. Addict Biol 26 7189 PMID: 16822976
Yokoi et al (1995) Refinement of odor molecule tuning by dendrodendritic synaptic inhibition in the olfactory bulb. J Neurosci 92 3371 PMID: 7724568
目前没有该产品的评论。 Be the first to review (RS)-4-Carboxyphenylglycine and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.